

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00537-186003	Application No.
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Zheng Xin Dong	
		Filing Date	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>[Signature]</i>	AA	5,705,483	01/06/98	Galloway et al.			
<i>[Signature]</i>	AB	5,545,618	08/13/96	Buckley et al.			
	AC						
	AD						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>[Signature]</i>	AE	HU P9501508	02/28/97	Hungary				
<i>[Signature]</i>	AF	WO 87/06941	11/19/87	PCT				
<i>[Signature]</i>	AG	WO 91/11457	08/08/91	PCT				
	AH	0 658 568 A1	06/21/95	Europe				
	AI	0 699 686 A2 & A3	03/06/96	Europe				
	AJ	0 708 179 A2 & A3	04/24/96	Europe				
	AK	0 733 644 A1	09/25/96	Europe				
	AL	WO 97/29180	08/14/97	PCT				
	AM	WO 98/03547	01/29/98	PCT				
	AN	WO 98/08871	03/05/98	PCT				
	AO	WO 98/19698	05/14/98	PCT				
<i>[Signature]</i>	AP	0 869 135 A1	10/07/98	Europe				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
<i>[Signature]</i>	AQ	Gutniak, Mark, et al.; "Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus"; 1992; The New England Journal of Medicine; Vol. 326 No. 28; Pages 1316-1322
<i>[Signature]</i>	AR	Mentlein, R., et al.; "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, Glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum"; 1993; Biochem; Vol. 214; Pages 829-835
<i>[Signature]</i>	AS	Naucek, M. A., et al.; "Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM"; 1996; Diabetologia; Vol. 39; Pages 1546-1553

Examiner Signature <i>David L. Lukan</i>	Date Considered <i>11-6-05</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00537-186003	Application No.
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Zheng Xin Dong	
		Filing Date	Group Art Unit
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
<i>DL</i>	AT	Parker, J. C., et al.; "Structure-function analysis of a series of glucagon-like peptide-I analogs"; 1998: Peptide Res; Vol. 52: 5; Pages 398-409; XP-000788444
<i>X</i>	AU	Rachman, J., et al.; "Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-I (GLP-I) in subjects with NIDDM"; 1997; Diabetologia; Vol. 40; Pages 205-211
<i>X</i>	AV	Suzuki, S., et al.; "Comparison of the Effects of Various C-Terminal and N-Terminal Fragment Peptides of Glucagon-Like Peptide-I on Insulin and Glucagon Release from the Isolated Perfused Rat Pancreas"; 1989; Endocrinology; Vol. 125: 6; Pages 3109-3114
<i>DL</i>	AW	Thorens, Bernard, et al.; "Glucagon-Like Peptide and the Control of Insulin Secretion in the Normal State and in NIDDM"; 1993; Diabetes; Vol. 42: Pages 1219-1225
<i>X</i>	AX	Thorens, Bernard, et al.; "Structure and Function of the Glucagon-Like Peptide-I Receptor"; 1996; Handbook of Experimental Pharmacology; Vol. 123; Pages 255-273
<i>X</i>	AY	Todd, J. F., et al.; "Glucagon-like peptide-I (GLP-I): a trial Of treatment in non-insulin-dependent diabetes mellitus"; 1997; European Journal of Clinical Investigation; Vol. 27; Pages 533-536
<i>X</i>	AZ	Ahren, Bo, et al.; "Effects of Glucagon-Like Peptide-I on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus"; 1997; Journal of Clinical Endocrinology and Metabolism; Vol. 82: 2; Pages 473-478
<i>X</i>	AAA	Deacon, C. F., et al.; "Dipeptidyl. peptidase IV resistant analogues of glucagon-like peptide-I which have extended metabolic stability and improved biological activity"; 1998; Diabetologia; Vol. 41; Pages, 271-278
<i>X</i>	ABB	Deacon, C. F., et al.; "Dipeptidyl Peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide I in the Anesthetized Pig"; 1998; Diabetes; Vol. 47; Pages 764-769

David L. Lukan

11-4-05

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<div style="float: left; width: 30%;"> PTO-1449 REPRODUCED MAR 16 2005 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <small>(Several sheets if necessary)</small> </div> <div style="float: right; width: 70%;"> <div style="text-align: right;">Sheet 1 of 1</div> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> ATTORNEY DOCKET NO. 089/US/PCT2/US-A </div> <div style="width: 45%;"> APPLICATION NO. 10/629,261 </div> </div> <div style="display: flex; justify-content: space-between; margin-top: 5px;"> <div style="width: 45%;"> APPLICANT DONG, Zheng Xin. </div> <div style="width: 45%;"> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> FILING DATE July 28, 2003 </div> <div style="width: 45%;"> GROUP/EXAMINER 1614/Unknown </div> </div> </div> </div> </div>							
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
X	BB	5,512,549	04/30/96	Chen et al.			
FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
X	BC	ADELHORST, K. et al., "Structure-activity studies of glucagon-like peptide-1," J. Biological Chemistry, 1994, 269(9):6275-6278.					
EXAMINER				DATE CONSIDERED			
				11-4-05			

Sheet 1 of 1							
PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				ATTORNEY DOCKET NO. 089/US/PCT2/US-A		APPLICATION NO. 10/629,261	
				APPLICANT DONG, Zheng Xin.			
				FILING DATE July 28, 2003		GROUP/EXAMINER 1614/Unknown	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
X	BA	RITZEL, U. et al., "A synthetic glucagon-like peptide-I analog with improved plasma stability," J. Endocrinology, 1998, 159:93-102.					
EXAMINER		DATE CONSIDERED					

Not considered

APPLICATION NO.
10/629,261

APPLICANT
DONG, et al.

(Use several sheets if necessary)

FILING DATE
July 28, 2003

GROUP / EXAMINER
1614 / Unknown

U.S. PATENT DOCUMENTS

EXAM- INER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA	6,620,910	9/16/03	Calas, et al.				
AB	6,720,407	4/13/04	Hughes, et al.				
AC	6,458,924	10/1/02	Knudsen, et al.				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER

DATE CONSIDERED

11-4-05